{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T07:50:16Z","timestamp":1722930616729},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,4,26]],"date-time":"2004-04-26T00:00:00Z","timestamp":1082937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2004,5]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> In a recent randomized controlled study, only a minority (15%) of adult hemophiliacs with chronic HCV achieved a sustained virologic response to treatment with interferon (IFN) and ribavirin given at standard doses.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> Whether the therapeutic response might be improved in these patients by increasing the doses of IFN was evaluated. Thirty\u2010four previously untreated, adult hemophiliacs with chronic HCV but negative for HIV were investigated. There were 33 men and 1 woman, aged 21 to 60 years (mean, 36). Twenty\u2010three patients (68%) had genotype 1, and median serum HCV\u2010RNA was 473 \u00d7 10<jats:sup>3<\/jats:sup> IU per L (range, 3.6\u20102145). Patients were treated with IFN at 5 million units (MU) thrice weekly for 6 months, followed by 3\u2003mol\/L for 6 additional months in combination with daily oral doses of 1 or 1.2\u2003g of ribavirin.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> A total of 33 patients (97%) completed the study; one patient withdrew because of treatment\u2010related symptoms. Treatment dosage had to be reduced in 20 patients (59%). By intention\u2010to\u2010treat analysis, 14 patients (41%) had a sustained virologic response, particularly those infected by HCV genotype 2 or 3 (70% vs. 29% with genotype 1 or 4, p &lt; 0.05). Sustained response rates were similar in the 13 compliant patients and the 20 patients who had to reduce IFN and\/or ribavirin doses (54% vs. 35%).<\/jats:p><jats:p><jats:bold>CONCLUSIONS:<\/jats:bold> High\u2010dose IFN therapy plus ribavirin provided high rates of sustained virologic responses in adult hemophiliacs with chronic HCV, even if side\u2010effects led to dose reduction in half of these patients.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2004.03154.x","type":"journal-article","created":{"date-parts":[[2004,4,26]],"date-time":"2004-04-26T09:44:22Z","timestamp":1082972662000},"page":"790-794","source":"Crossref","is-referenced-by-count":12,"title":["Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients"],"prefix":"10.1111","volume":"44","author":[{"given":"E.","family":"Santagostino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"De Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. G.","family":"Rumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rivi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. M.","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Hepatitis Study Group of the Association of Italian Hemophilia Centers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,4,26]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"1425","article-title":"Mortality from liver cancer and liver disease in haemophilic men and boys given blood products contaminated with hepatitis C. U","volume":"350","author":"Darby SC","year":"1997","journal-title":"K Haemophilia Centre Directors\u2019 Organisation. Lancet"},{"key":"e_1_2_7_3_2","first-page":"1584","article-title":"End\u2010stage liver disease in persons with hemophilia and transfusion\u2010associated infections","volume":"100","author":"Goedert JJ","year":"2002","journal-title":"Blood"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.35529"},{"key":"e_1_2_7_5_2","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood.V87.5.1704.1704","article-title":"Interferon treatment for chronic hepatitis C infections in hemophiliacs. Influence of virus load genotype and liver pathology on response","volume":"87","author":"Hanley JP","year":"1996","journal-title":"Blood"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101"},{"key":"e_1_2_7_7_2","first-page":"1426","article-title":"Randomised trial of interferon alfa\u20102b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa\u20102b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus","volume":"352","author":"Poynard T","year":"1998","journal-title":"International Hepatitis Interventional Therapy Group (IHIT). Lancet"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.25636"},{"key":"e_1_2_7_9_2","first-page":"2S","volume-title":"Hepatol","author":"The National Institutes of Health Consensus Development Conference","year":"1997"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00008-4"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.1089"},{"key":"e_1_2_7_12_2","first-page":"3529","article-title":"A multicenter controlled, randomized, open trial of interferon \u03b12b treatment of anti\u2010human immunodeficiency virus\u2010negative hemophilic patients with chronic hepatitis C","volume":"89","author":"Rumi MG","year":"1997","journal-title":"Hepatitis Study Group of the Association of Italian Hemophilia Centers. Blood"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.1995.tb00009.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb07444.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1055\/s-0037-1613924","article-title":"Treatment with interferon plus ribavirin in anti\u2010HIV negative patients with congenital coagulation disorders and chronic hepatitis C","volume":"83","author":"Sauleda S","year":"2000","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00140-X"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.8089"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012073432301"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200301163480317"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.1.1"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2004.03154.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2004.03154.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2004.03154.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T03:45:29Z","timestamp":1697082329000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2004.03154.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,26]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["10.1111\/j.1537-2995.2004.03154.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2004.03154.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"type":"print","value":"0041-1132"},{"type":"electronic","value":"1537-2995"}],"subject":[],"published":{"date-parts":[[2004,4,26]]}}}